NAYA Oncology

NAYA Oncology is the oncology-focused division of NAYA Biosciences, a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies. The company's primary focus is on its proprietary bispecific antibody platform, which aims to provide more effective treatments for patients with high unmet needs in cancer care. Its lead candidate, NY-303, is a GPC3 x CD3 bispecific antibody currently being developed for the treatment of hepatocellular carcinoma. Additionally, the company is advancing NY-338, a CD38 x CD3 bispecific antibody targeting multiple myeloma. Following its merger with INVO Bioscience, NAYA Biosciences operates as a public entity, combining its innovative oncology pipeline with a commercial-stage fertility business. The company seeks to leverage its unique portfolio to drive value in both the biotechnology and healthcare services sectors.